The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy
- 1 July 2003
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 25 (7) , 2102-2119
- https://doi.org/10.1016/s0149-2918(03)80208-4
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes MellitusCirculation, 2002
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristicsNephrology Dialysis Transplantation, 2000
- Gains in Life Expectancy from Medical Interventions — Standardizing Data on OutcomesNew England Journal of Medicine, 1998
- Relative Contributions of Incidence and Survival to Increasing Prevalence of Adult-Onset Diabetes Mellitus: A Population-based StudyAmerican Journal of Epidemiology, 1997
- An Economic Analysis of Captopril in the Treatment of Diabetic NephropathyDiabetes Care, 1996
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993
- Cost and health implications of cholesterol lowering.Circulation, 1992